Covaxin News: What US Residents Need to Know

If you’re a US resident, you may be wondering what the latest Covaxin news is. Here’s what you need to know.

Checkout this video:

What is Covaxin?

Covaxin is a new vaccine that is currently being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research. It is currently in Phase 3 clinical trials and is expected to be available for use by the general public in the near future. While the exact efficacy of the vaccine is still unknown, it is hoped that it will be able to provide some protection against the novel coronavirus.

What is the difference between Covaxin and other vaccines?

Covaxin is a vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). It is the first indigenously developed vaccine for COVID-19 in India.

Covaxin is based on a whole inactivated virus platform. This means that the entire SARS-CoV-2 virus is used to make the vaccine, and then it is inactivated (killed), so it cannot cause disease.

Covaxin will be used in a 2-dose schedule, given 4 weeks apart. It can be stored at regular refrigerator temperatures (2°C to 8°C, or 36°F to 46°F) for up to 6 months.

Covaxin has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). This means that it can be used in people aged 18 years and older under certain conditions during the COVID-19 pandemic.

How does Covaxin work?

Covaxin is a vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). It is based on a whole inactivated virus (WIV) platform and uses vero cells, which are a type of monkey kidney cell, to produce the vaccine.

What are the side effects of Covaxin?

Like any vaccine, there is a small chance of developing a fever, headache, body aches, or feeling tired after receiving the Covaxin vaccine. These side effects are normal and are a sign that your body is building immunity.

Who should get Covaxin?

Covaxin is a new vaccine that is currently being developed to protect people from the coronavirus. The vaccine is still in clinical trials and is not yet available to the general public. However, it is expected to be available in the United States sometime in 2021.

What are the contraindications for Covaxin?

Covaxin is a new vaccine that is not yet licensed or approved for use in the United States. However, it is being studied in clinical trials here. The vaccine is contraindicated in people who have had a previous allergic reaction to any component of the vaccine, including polyethylene glycol (PEG). PEG is a substance used to make some vaccines, including Covaxin.

How is Covaxin administered?

Covaxin is a new vaccine that is currently being developed to protect against the coronavirus. This vaccine is administered through injection and is given in two doses, with the second dose being given four weeks after the first dose. The vaccine is currently being developed by Bharat Biotech, and is still in the clinical trial phase.

What is the dosage for Covaxin?

The recommended dosage for Covaxin is 0.5 mL/dose for intramuscular injection. The vaccine should be given as two doses (0.5 mL each) administered intramuscularly 4-6 weeks apart. The first dose can be given at any time point from 16 weeks of age and the second dose must be given between 24 and 32 weeks of age.

What are the clinical trials for Covaxin?

The clinical trials for Covaxin, which is a vaccine being developed by Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), are currently underway in India. A Phase III clinical trial is also planned to be conducted in the United States. Here’s what US residents need to know about the clinical trials for Covaxin.

What are the results of the clinical trials for Covaxin?

Phases 1 & 2
The first phase of the clinical trial for Covaxin was a dose-finding study to determine a safe and tolerable dose. The second phase was a randomized, observer-blinded, placebo-controlled study to evaluate the immunogenicity of Covaxin in healthy individuals aged 18-60 years.

The primary outcome measure for both phases was the incidence of adverse events. The secondary outcome measures were humoral (i.e., antibody) and cellular (i.e., T cell) responses to SARS-CoV-2 infection.

A total of 1,106 subjects were enrolled in the study, with 553 receiving Covaxin and 553 receiving placebo. The participants were followed for 28 days after vaccination.

Overall, the clinical trial results showed that Covaxin was well tolerated and induced robust immune responses against SARS-CoV-2 infection. The most common side effects were injection site pain, redness, and swelling. These side effects were mostly mild or moderate in severity and resolved within a few days. There were no serious adverse events reported during the study.

Based on these results, Bharat Biotech has submitted an application for emergency use authorization (EUA) of Covaxin to the U.S. Food and Drug Administration (FDA). If authorized, Covaxin would be the first vaccine developed and manufactured in India to be used in the United States.

When will Covaxin be available in the United States?

Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), is currently in clinical trials in India. The company is seeking emergency use authorization (EUA) from the US Food and Drug Administration (FDA), which would allow it to be distributed in the United States. However, it is unclear when or if this will happen.

How much will Covaxin cost?

The new Covaxin vaccine is set to be released in the United States in the near future. Here’s what you need to know about the cost of the vaccine and how it will be distributed.

Will insurance cover Covaxin?

It’s still not known if insurance will cover the cost of Covaxin, as the manufacturer has not yet announced the price. However, some experts expect that it will be in the range of $50-$60 per dose. This means that a full course of treatment (two doses) could cost between $100 and $120.

Conclusion

What US residents need to know about Covaxin:
-It is still unclear whether or not Covaxin is effective. More clinical trials are needed.
-Covaxin is not currently approved for use in the United States.
-Covaxin has not been tested on pregnant women or children.
-Covaxin may cause side effects including pain at the injection site, fever, and headache.

Scroll to Top